Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cannabinoid-Induced Conditioned Place Preference, Intravenous Self-Administration, and Behavioral Stimulation Influenced by Ghrelin Receptor Antagonism in Rats

C. Charalambous, T. Havlickova, M. Lapka, N. Puskina, R. Šlamberová, M. Kuchar, M. Sustkova-Fiserova

. 2021 ; 22 (5) : . [pub] 20210227

Language English Country Switzerland

Document type Journal Article

Grant support
PROGRES Q35 PROGRES Q35
GACR 21-30795S GACR
260533/SVV/2020 SVV CEP Register

Cannabis/cannabinoids are widely used for recreational and therapy purposes, but their risks are largely disregarded. However, cannabinoid-associated use disorders and dependence are alarmingly increasing and an effective treatment is lacking. Recently, the growth hormone secretagogue receptor (GHSR1A) antagonism was proposed as a promising mechanism for drug addiction therapy. However, the role of GHS-R1A and its endogenous ligand ghrelin in cannabinoid abuse remains unclear. Therefore, the aim of our study was to investigate whether the GHS-R1A antagonist JMV2959 could reduce the tetrahydrocannabinol (THC)-induced conditioned place preference (CPP) and behavioral stimulation, the WIN55,212-2 intravenous self-administration (IVSA), and the tendency to relapse. Following an ongoing WIN55,212-2 self-administration, JMV2959 3 mg/kg was administered intraperitoneally 20 min before three consequent daily 120-min IVSA sessions under a fixed ratio FR1, which significantly reduced the number of the active lever-pressing, the number of infusions, and the cannabinoid intake. Pretreatment with JMV2959 suggested reduction of the WIN55,212-2-seeking/relapse-like behavior tested in rats on the twelfth day of the forced abstinence period. On the contrary, pretreatment with ghrelin significantly increased the cannabinoid IVSA as well as enhanced the relapse-like behavior. Co-administration of ghrelin with JMV2959 abolished/reduced the significant efficacy of the GHS-R1A antagonist in the cannabinoid IVSA. Pretreatment with JMV2959 significantly and dose-dependently reduced the manifestation of THC-induced CPP. The THC-CPP development was reduced after the simultaneous administration of JMV2959 with THC during conditioning. JMV2959 also significantly reduced the THC-induced behavioral stimulation in the LABORAS cage. Our findings suggest that GHS-R1A importantly participates in the rewarding/reinforcing effects of cannabinoids.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019187
003      
CZ-PrNML
005      
20210830100745.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22052397 $2 doi
035    __
$a (PubMed)33673659
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Charalambous, Chrysostomos $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
245    10
$a Cannabinoid-Induced Conditioned Place Preference, Intravenous Self-Administration, and Behavioral Stimulation Influenced by Ghrelin Receptor Antagonism in Rats / $c C. Charalambous, T. Havlickova, M. Lapka, N. Puskina, R. Šlamberová, M. Kuchar, M. Sustkova-Fiserova
520    9_
$a Cannabis/cannabinoids are widely used for recreational and therapy purposes, but their risks are largely disregarded. However, cannabinoid-associated use disorders and dependence are alarmingly increasing and an effective treatment is lacking. Recently, the growth hormone secretagogue receptor (GHSR1A) antagonism was proposed as a promising mechanism for drug addiction therapy. However, the role of GHS-R1A and its endogenous ligand ghrelin in cannabinoid abuse remains unclear. Therefore, the aim of our study was to investigate whether the GHS-R1A antagonist JMV2959 could reduce the tetrahydrocannabinol (THC)-induced conditioned place preference (CPP) and behavioral stimulation, the WIN55,212-2 intravenous self-administration (IVSA), and the tendency to relapse. Following an ongoing WIN55,212-2 self-administration, JMV2959 3 mg/kg was administered intraperitoneally 20 min before three consequent daily 120-min IVSA sessions under a fixed ratio FR1, which significantly reduced the number of the active lever-pressing, the number of infusions, and the cannabinoid intake. Pretreatment with JMV2959 suggested reduction of the WIN55,212-2-seeking/relapse-like behavior tested in rats on the twelfth day of the forced abstinence period. On the contrary, pretreatment with ghrelin significantly increased the cannabinoid IVSA as well as enhanced the relapse-like behavior. Co-administration of ghrelin with JMV2959 abolished/reduced the significant efficacy of the GHS-R1A antagonist in the cannabinoid IVSA. Pretreatment with JMV2959 significantly and dose-dependently reduced the manifestation of THC-induced CPP. The THC-CPP development was reduced after the simultaneous administration of JMV2959 with THC during conditioning. JMV2959 also significantly reduced the THC-induced behavioral stimulation in the LABORAS cage. Our findings suggest that GHS-R1A importantly participates in the rewarding/reinforcing effects of cannabinoids.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a zvířata $7 D000818
650    _2
$a chování zvířat $x účinky léků $7 D001522
650    _2
$a kanabinoidy $x aplikace a dávkování $x farmakologie $7 D002186
650    _2
$a operantní podmiňování $x účinky léků $7 D003216
650    _2
$a podmiňování (psychologie) $x účinky léků $7 D003213
650    _2
$a glycin $x analogy a deriváty $x farmakologie $7 D005998
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptory ghrelinu $x antagonisté a inhibitory $7 D054440
650    _2
$a posilování (psychologie) $7 D012054
650    _2
$a autoaplikace $7 D012646
650    _2
$a triazoly $x farmakologie $7 D014230
655    _2
$a časopisecké články $7 D016428
700    1_
$a Havlickova, Tereza $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
700    1_
$a Lapka, Marek $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
700    1_
$a Puskina, Nina $u Department of Addictology, First Faculty of Medicine, Charles University, Apolinarska 4, 128 00 Prague 2, Czech Republic
700    1_
$a Šlamberová, Romana $u Department of Physiology, Third Faculty of Medicine, Charles University, Ke Karlovu 4, 120 00 Prague 2, Czech Republic
700    1_
$a Kuchar, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technicka 5, 166 28 Prague 6, Czech Republic
700    1_
$a Sustkova-Fiserova, Magdalena $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 5 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33673659 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100746 $b ABA008
999    __
$a ok $b bmc $g 1690094 $s 1139633
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 5 $e 20210227 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a PROGRES Q35 $p PROGRES Q35
GRA    __
$a GACR 21-30795S $p GACR
GRA    __
$a 260533/SVV/2020 $p SVV
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...